Why Climate Never Got Its Own Biotech Moment
October 2, 2026
In the summer of 2025, Royalty Pharma committed up to $2 billion to Revolution Medicines for a single asset: a cancer drug called daraxonrasib that,
In the summer of 2025, Royalty Pharma committed up to $2 billion to Revolution Medicines for a single asset: a cancer drug called daraxonrasib that,
When most investors think about climate tech, they picture solar panels, wind turbines, electric vehicles, and carbon capture systems. These are important technologies. They are
“Typically, VCs focus solely on generating returns, but we felt that wasn’t enough. Profitability or EBITDA isn’t a mission – it’s just the result of
